Healthcare-Associated Infections Cost Lives - and Time Matters

MRSA alone caused approximately 130,000 deaths globally in 2021, more than double the figure from 1990 (Lancet GRAM Project, 2024). In the United States, hospital-onset MRSA bacteremia rates rose during the COVID-19 pandemic and remain a serious concern (CDC, 2024).

Traditional culture-based identification can take 24 to 48 hours. Every hour matters: faster identification means a faster isolation, faster integrated therapy, and shorter hospital stays.

Designed for the Way Care Actually Happens

AptaSure™ uses patented aptamer-based technology to identify infectious organisms at the point of care — at the bedside, in the ED, in pre-op, or in skilled nursing. Each kit is single-use, requires no refrigeration, and runs without a separate analyzer or laboratory infrastructure.

Three benefits matter most:

• Speed — Results in minutes from sample to answer.
• Simplicity — No multi-step protocols, no temperature-sensitive reagents, no specialized training required.
• Cost — Affordable enough to deploy where rapid molecular testing has been cost-prohibitive.

Faster diagnosis. Shorter stays. Better outcomes.

• ~120,000 — U.S. S. aureus bloodstream infections annually (CDC)
• ~20,000 — Associated U.S. deaths each year
• $4,600+ — Per-stay added cost from a multidrug-resistant infection
• Up to 48 hours — Saved versus traditional culture

Sources: CDC Vital Signs MMWR; CDC AR Threats Report 2021–2022; Lancet GRAM Project 2024.